# Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

> **NCT03458221** · PHASE2,PHASE3 · RECRUITING · sponsor: **Gynaecologisch Oncologisch Centrum Zuid** · enrollment: 148 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer
- Signal Transduction Pathway Deregulation
- Therapy-Associated Cancer

## Interventions

- **DRUG:** Letrozole Oral Product
- **DRUG:** Bicalutamide Oral Product
- **DRUG:** Everolimus Oral Product
- **DRUG:** Itraconazole Oral Product

## Key facts

- **NCT ID:** NCT03458221
- **Lead sponsor:** Gynaecologisch Oncologisch Centrum Zuid
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-31
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03458221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03458221, "Signal TrAnsduction Pathway Activity Analysis in OVarian cancER". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03458221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*